Elutia Plans FDA Filing for Antibiotic-Coated Matrix
Elutia's NXT-41x matrix passed a rabbit study and is slated for an FDA filing in the fourth quarter of 2026.
Updated on Nov. 8, 2026 in Healthcare
Elutia plans to file NXT-41x, an antibiotic-coated biologic matrix for plastic and reconstructive procedures, with the FDA in the fourth quarter of 2026. A GLP rabbit study met its prespecified antibacterial endpoints, with no viable bacteria recovered from the matrix or surrounding tissue.
Why it matters
The filing would advance a product designed to address infection risk in plastic and reconstructive surgery, where bacterial contamination is a concern. The company's timeline depends on FDA review, which will determine when the product could reach surgeons.
A GLP rabbit study challenged NXT-41x with an 8-log MRSA load and a 6-log E. coli load, and recovered no viable bacteria from the matrix or surrounding tissue. The study met its prespecified endpoints, but human outcomes have not been reported.
The players
Elutia
Elutia is the company developing the NXT-41x antibiotic-coated matrix and its base matrix NXT-41.
Dr. Randy Mills
Dr. Randy Mills is the chief executive of Elutia who has offered the company's clearance timeline.
The details
NXT-41x is a biologic matrix with an antibiotic coating on one side, designed for plastic and reconstructive procedures. Elutia's base matrix, NXT-41, contains no drug and is under separate FDA review.
Timeline
Q4 2026: Planned FDA filing for NXT-41x
Q4 2026: Expected FDA decision on base matrix NXT-41
First half of 2027: Targeted clearance decision for NXT-41x
Q2 2027: Anticipated clearance decision for NXT-41x, per CEO Dr. Randy Mills
Industry Dynamics
Antibiotic-coated surgical matrices sit within the FDA device clearance process, which governs when new implant products can reach surgeons. Elutia's planned filing follows its base matrix NXT-41, which is already under separate FDA review.
If cleared, NXT-41x would give surgeons a matrix with an antibiotic coating for plastic and reconstructive procedures. The product's availability to patients depends entirely on the FDA's review outcome and timing.
The takeaway
A successful rabbit study is an early milestone, and human clearance remains the decisive step for NXT-41x. Readers tracking surgical infection prevention should watch the FDA review in 2027.
What happens next
Elutia plans to file NXT-41x with the FDA in the fourth quarter of 2026, with a targeted clearance decision in the first half of 2027.
Further reading
Track more regulatory and device-approval developments in the Healthcare section.
Source note: This article includes information reported by TokenPost.
